Physician profile
Chasareth E Thompson
NPI 1578907630
$2,040.61
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,076 · 2022: $638 · 2023: $310 · 2024: $16.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $223.74 | 2021-2023 | Saxenda, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.40 | 2021-2023 | Jardiance |
| Abbvie INC. | $169.51 | 2021-2023 | |
| Pfizer INC. | $165.96 | 2021-2023 | |
| Amarin Pharma, INC. | $143.63 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $110.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $104.17 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $90.51 | 2021-2022 | |
| Glaxosmithkline, LLC. | $88.95 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $86.95 | 2022 | |
| Lilly USA, LLC | $81.39 | 2021-2023 | Jardiance, Emgality |
| Esperion Therapeutics, INC. | $70.15 | 2021-2023 | Nexletol |
| Amgen INC. | $65.90 | 2021-2022 | |
| Astellas Pharma US INC | $50.57 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $39.52 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.29 | 2021-2022 | |
| Cardiovascular Systems INC. | $24.97 | 2022 | |
| Inari Medical, INC. | $24.43 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $23.33 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.30 | 2022 | |
| Exact Sciences Corporation | $19.01 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $18.38 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.35 | 2024 | Horizant |
| Kowa Pharmaceuticals America, INC. | $15.45 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.39 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.45 | 2023 | Xarelto |
| Genentech USA, INC. | $12.18 | 2021 | |
| Vivus LLC | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chasareth Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.